Advancements in CDK-based Dual-target Inhibitors for Cancer Therapy

Background: The cyclin-dependent kinases (CDKs) play a crucial role in the normal progression of these stages. In tumor cells, CDKs are often highly expressed, leading to uncontrolled cell proliferation. Inhibiting the activity of CDKs in tumor cells can inhibit their growth and proliferation, thereby achieving anti-tumor effects. In recent years, many CDKs inhibitors have been developed, but due to side effects and drug resistance issues, only a few CDKs inhibitors have been approved by the FDA. Methods: Publications on CDK-based dual-target inhibitors were reviewed using SciFinder and PubMed, excluding reviews, patents, and studies with irrelevant content. Results: The study outlines advancements in CDK-based dual-target inhibitors as antitumor agents, offering insights to support the development and application of more effective cancer therapies. Conclusion: Dual-targeted anti-tumor drugs may have better therapeutic effects than single- targeted drugs, which may address drug resistance issues and overcome drug interactions and pharmacokinetic issues associated with combination therapy. As an important direction in cancer treatment, dual target inhibitors have broad development prospects. By continuing to explore and improve dual target therapies, it has potential to overcome many limitations of single target therapy and provide more effective and lasting treatment outcomes for cancer patients.